Q-omics provides the consensus-scored PEX5L profile across patient tissues and cancer cell-line models. PEX5L expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PEX5L is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PEX5L RNA expression shows 20,318 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where PEX5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX5L survival associations across molecular data types. PEX5L RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX5L RNA expression–survival associations across cancer types. High PEX5L expression shows unfavorable associations in BLCA, KIRP, UCEC, HNSC and COAD, but favorable associations in MESO. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PEX5L RNA expression.
This table summarizes PEX5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PEX5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX5L shows lower tumor expression in THCA, KICH, PAAD and KIRP and higher tumor expression in BRCA and LIHC. The THCA box plot shows higher PEX5L RNA expression in normal versus tumor tissue (log2 FC = −0.237, t-test p < 0.001).
This table shows molecular features associated with PEX5L in patient tissues and cancer cell lines. In patient samples, PEX5L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
